Gilead Sciences (GILD) Net Income towards Common Stockholders Growth (5y) (2014 - 2026)

Gilead Sciences (GILD) Net Income towards Common Stockholders Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 3.40%
Dec 31, 2025 10.64%
Sep 30, 2025 56.32%
Jun 30, 2025 20.75%
Mar 31, 2025 -1.61%
Dec 31, 2024 25.34%
Sep 30, 2024 24.27%
Jun 30, 2024 -1.48%
Mar 31, 2024 -33.76%
Dec 31, 2023 38.19%
Sep 30, 2023 2.15%
Jun 30, 2023 -9.97%
Mar 31, 2023 -7.83%
Dec 31, 2022 19.51%
Sep 30, 2022 -4.96%
Jun 30, 2022 -15.63%
Mar 31, 2022 -64.81%
Dec 31, 2021 -32.19%
Sep 30, 2021 -1.81%
Jun 30, 2021 -12.34%